SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update
SeaStar Medical (ICU) reported Q3 2024 financial results, highlighting its first commercial sales of QUELIMMUNE™, generating revenue of $67,500. The company reported progress in its NEUTRALIZE-AKI pivotal trial with 59 subjects enrolled and expanded to 12 clinical sites. SeaStar eliminated over $9 million in long-term debt since early 2024. Q3 net loss was $4.5 million ($1.10 per share) compared to $7.2 million ($9.02 per share) in Q3 2023. Cash position as of September 30, 2024, was $2.1 million, bolstered by a $10 million registered direct offering in July 2024.
SeaStar Medical (ICU) ha riportato i risultati finanziari per il terzo trimestre del 2024, evidenziando le sue prime vendite commerciali di QUELIMMUNE™, generando un fatturato di $67,500. L'azienda ha segnalato progressi nel suo trial pivotale NEUTRALIZE-AKI con 59 soggetti arruolati, espandendosi a 12 siti clinici. SeaStar ha ridotto oltre $9 milioni di debito a lungo termine dall'inizio del 2024. La perdita netta del terzo trimestre è stata di $4,5 milioni ($1,10 per azione) rispetto ai $7,2 milioni ($9,02 per azione) del terzo trimestre del 2023. La posizione di cassa al 30 settembre 2024 era di $2,1 milioni, sostenuta da un'offerta diretta registrata di $10 milioni a luglio 2024.
SeaStar Medical (ICU) reportó resultados financieros del tercer trimestre de 2024, destacando sus primeras ventas comerciales de QUELIMMUNE™, generando ingresos de $67,500. La compañía informó avances en su ensayo pivotal NEUTRALIZE-AKI con 59 sujetos inscritos y se expandió a 12 sitios clínicos. SeaStar eliminó más de $9 millones en deuda a largo plazo desde principios de 2024. La pérdida neta en el tercer trimestre fue de $4,5 millones ($1,10 por acción) en comparación con $7,2 millones ($9,02 por acción) en el tercer trimestre de 2023. La posición de efectivo al 30 de septiembre de 2024 era de $2,1 millones, reforzada por una oferta directa registrada de $10 millones en julio de 2024.
SeaStar Medical (ICU)는 2024년 3분기 재무 결과를 발표하며, QUELIMMUNE™의 첫 상업적 판매로 $67,500의 수익을 창출했다고 밝혔습니다. 회사는 59명의 참가자가 등록된 NEUTRALIZE-AKI 주요 시험에서 진행 상황을 보고하였으며, 12개의 임상 사이트로 확장되었습니다. SeaStar는 2024년 초 이후 장기 부채를 900만 달러 이상 줄였습니다. 3분기 순손실은 450만 달러($1.10 per share)로, 2023년 3분기 720만 달러($9.02 per share)와 비교되었습니다. 2024년 9월 30일 현재 현금 잔고는 210만 달러로, 2024년 7월에 이루어진 1천만 달러의 등록된 직접 공모에 의해 지원되었습니다.
SeaStar Medical (ICU) a annoncé les résultats financiers du troisième trimestre 2024, mettant en lumière ses premières ventes commerciales de QUELIMMUNE™, générant des revenus de 67 500 $. L'entreprise a signalé des progrès dans son essai pivot NEUTRALIZE-AKI avec 59 sujets inscrits et s'est étendue à 12 sites cliniques. SeaStar a éliminé plus de 9 millions de dollars de dettes à long terme depuis début 2024. La perte nette du troisième trimestre s'est élevée à 4,5 millions de dollars (1,10 $ par action) contre 7,2 millions de dollars (9,02 $ par action) au troisième trimestre 2023. La position de liquidités au 30 septembre 2024 était de 2,1 millions de dollars, soutenue par une offre directe enregistrée de 10 millions de dollars en juillet 2024.
SeaStar Medical (ICU) hat die finanziellen Ergebnisse für das dritte Quartal 2024 bekannt gegeben und hebt dabei die ersten kommerziellen Verkäufe von QUELIMMUNE™ hervor, die Einnahmen von 67,500 US-Dollar generierten. Das Unternehmen berichtete über Fortschritte in seiner entscheidenden Studie NEUTRALIZE-AKI, in die 59 Probanden eingeschlossen wurden und die auf 12 klinische Standorte ausgeweitet wurde. SeaStar hat seit Anfang 2024 über 9 Millionen US-Dollar an langfristigen Schulden abgebaut. Der Nettoverlust im dritten Quartal betrug 4,5 Millionen US-Dollar (1,10 US-Dollar pro Aktie), verglichen mit 7,2 Millionen US-Dollar (9,02 US-Dollar pro Aktie) im dritten Quartal 2023. Die Kassenposition zum 30. September 2024 betrug 2,1 Millionen US-Dollar, gestützt durch ein registriertes direktes Angebot von 10 Millionen US-Dollar im Juli 2024.
- First commercial revenue of $67,500 from QUELIMMUNE sales
- Elimination of over $9 million in long-term debt
- Reduced net loss per share from $9.02 in Q3 2023 to $1.10 in Q3 2024
- Received FDA Breakthrough Device Designation for chronic dialysis indication
- Projected cost savings of $30,000 per hospitalization with QUELIMMUNE
- Increased R&D expenses to $2.3M from $1.1M year-over-year
- Higher G&A expenses at $2.2M vs $1.9M in Q3 2023
- Net loss of $4.5M in Q3 2024
- Low cash position of $2.1M as of September 30, 2024
Insights
The Q3 results reveal mixed signals for SeaStar Medical. The company achieved its first commercial revenue of
The shift to a direct sales model could significantly improve revenue recognition, potentially increasing per-unit revenue by
The FDA Breakthrough Device Designation for chronic dialysis expands market potential, but continued R&D spending (
The NEUTRALIZE-AKI trial's progress with 59 enrolled subjects and expansion to 12 clinical sites demonstrates meaningful advancement toward the interim analysis milestone of 100 subjects. Early clinical data showing
The fourth Breakthrough Device Designation for chronic dialysis represents significant regulatory validation and expands the potential application beyond acute conditions. The addressable market of 4,000 pediatric patients, combined with an adult AKI population 50 times larger, presents substantial growth potential. The demonstrated cost-effectiveness and safety profile could accelerate adoption in the critical care setting.
DENVER, Nov. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2024, and provides a business update.
“We are delighted to report market demand and our first commercial sales of QUELIMMUNE™, our pediatric SCD that was cleared for sale by FDA in February 2024,” said Eric Schlorff, SeaStar Medical CEO. "During the third quarter, we recognized
“Beginning in the fourth quarter, we are able to recognize
“The adult AKI patient population is 50 times larger than the pediatric population, and our NEUTRALIZE-AKI pivotal trial is gaining momentum with 59 subjects now enrolled. This includes a record enrollment month in October, moving us closer to the interim data review we anticipate at 100 subjects. Three new medical centers have joined this trial in the fourth quarter, increasing the number of clinical sites to 12 and underscoring our confidence the pace of enrollment will accelerate,” he added. “We continue to explore the potential of our technology in multiple, high-value indications beyond AKI. To this end, we received notice last week from the FDA of Breakthrough Device Designation for the SCD in chronic dialysis. This is the fourth indication to receive this designation and the first for a chronic disease.”
“I’m pleased to report the elimination of more than
SeaStar Medical provides the following updates on its commercial and development programs, and corporate activities:
QUELIMMUNE and Pediatric Acute Kidney Injury
Only about half of the patients in the pediatric ICU with AKI who require renal replacement therapy (RRT) survive, and those who do are at elevated risk of long-term, life-threatening conditions such as chronic kidney disease. Pooled analyses from two non-controlled studies, one of which was funded by the FDA Office of Orphan Products Development, showed that children weighing 10 kilograms or more with AKI requiring continuous RRT (CRRT) who were treated with QUELIMMUNE (Selective Cytopheretic Device or SCD-Pediatric) had a
In February 2024 we received our first U.S. regulatory approval for the QUELIMMUNE device, the SCD specifically for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are being treated in the ICU with RRT. QUELIMMUNE was approved under a Humanitarian Device Exemption (HDE) application, having met the applicable criteria with clinical results showing safety and probable clinical benefit to critically ill children with AKI who have few treatment options. The U.S. addressable population of about 4,000 pediatric patients falls within the 8,000-patient HDE criteria.
We are working with hospitals to commercialize QUELIMMUNE under Humanitarian Use Device (HUD) requirements. Pediatric patients undergoing treatment with this therapy are expected to require, on average, five to seven QUELIMMUNE units, with the disposable portion of the unit being changed once every 24 hours.
- In July 2024 we announced the first commercial sale of QUELIMMUNE to our previous U.S. distribution partner, following the finalization of FDA labeling requirements earlier in the month.
- In July 2024 we reported that the first patient had been treated with QUELIMMUNE in a commercial setting, which allowed us to meet the August 20, 2024 FDA deadline to begin patient treatments as designated in the FDA’s approval of QUELIMMUNE.
- In October 2024 we assumed all responsibility for direct sales, marketing and distribution of QUELIMMUNE to hospital customers, allowing us to recognize
100% of revenue generated from commercial QUELIMMUNE sales. - In October 2024 we introduced an analysis of economic data supporting a projected cost savings of approximately
$30,000 per hospitalization for critically ill pediatric patients with AKI on CRRT treated with QUELIMMUNE versus standard of care. The cost savings is principally driven by the lower expected death rate and shorter length of hospital stay. The analysis was introduced at ASN Kidney Week 2024, the premier nephrology conference. - In October 2024 we shipped QUELIMMUNE to a second commercial hospital customer.
Adult Acute Kidney Injury
We are conducting the pivotal NEUTRALIZE-AKI (NEUTRophil and Monocyte DeActivation via SeLective CytopheretIc Device - a RandomiZEd Clinical Trial in Acute Kidney Injury) clinical trial to evaluate the safety and effectiveness of the SCD in adults with AKI in the ICU receiving CRRT. The SCD-ADULT device has received FDA Breakthrough Device Designation for this indication, which is awarded to a therapy to treat a serious or life-threatening condition with preliminary clinical evidence indicating it may demonstrate substantial improvement over available therapies on clinically significant endpoints.
The NEUTRALIZE-AKI trial is expected to enroll up to 200 patients at up to 30 U.S. medical centers. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD-ADULT in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of SCD-ADULT therapy in AKI patients with sepsis and acute respiratory distress syndrome.
- In July 2024 the U.S. Centers for Medicare & Medicaid Services (CMS) granted Category B coverage for certain expenses incurred by medical centers treating Medicare or Medicaid patients enrolled in the adult AKI trial.
- We expect to receive U.S. regulatory approval for the SCD for adults with AKI under a Premarket Approval (PMA) application and to begin the commercial product launch in 2026.
Additional SCD Indications
We continue to explore the application of our SCD technology across a range of indications involving dysregulated immune processes where proinflammatory activated neutrophils and monocytes may contribute to disease progression or severity, in both acute and chronic indications. The SCD has shown a measurable reduction in excessive inflammatory responses such as the reduction of solid organ dysfunction in a variety of preclinical and clinical studies, including sepsis, acute kidney injury, hepatorenal syndrome, cardiorenal syndrome, ischemia/reperfusion injury, intracerebral hemorrhage, cardiopulmonary bypass, chronic kidney disease, chronic dialysis, type 2 diabetes, acute respiratory distress syndrome and COVID-19, among others.
- In November 2024 we received FDA Breakthrough Device Designation for the SCD for use in chronic dialysis, our first such designation for a chronic indication. This is our fourth FDA award of Breakthrough Device Designation including adult AKI, cardiorenal syndrome and hepatorenal syndrome.
Scientific Presentations
In October 2024 the SCD was featured in four poster presentations at ASN Kidney Week 2024, including the following:
- Economic data indicating the QUELIMMUNE substantially lowers hospitalization costs for critically ill pediatric patients with AKI treated with CRRT.
- New data further explaining mechanistically how the SCD addresses hyperinflammation and helps restore immune balance in these critically ill AKI patients.
Corporate Developments
- In July 2024 we completed a registered direct offering priced at-the-market, raising gross proceeds of
$10 million . - In September we eliminated all long-term debt, which was reported at more than
$9 million at the end of 2023. - Since August 20, 2024, and through November 10, 2024, we raised approximately
$1.8 million , net of fees, by issuing approximately 569 thousand shares our common stock.
Third Quarter Financial Results
Net revenue for the third quarter of 2024 was
Research and development (R&D) expenses for the third quarter of 2024 were
Other expenses, net for the third quarter of 2024 was
The net loss for the third quarter of 2024 was
Nine Month Financial Results
Net revenue for the first nine months of 2024 was
R&D expenses for the first nine months of 2024 were
Other expense, net for the nine months ended September 30, 2024 was
The net loss for the first nine months of 2024 was
Cash as of September 30, 2024, was
About the Selective Cytopheretic Device (SCD)
The SCD is a patented cell-directed extracorporeal device that employs immunomodulating technology to selectively target proinflammatory neutrophils and monocytes during CRRT and reduces the hyperinflammatory milieu including the cytokine storm that causes inflammation, organ failure and possible death in critically ill patients. Unlike pathogen removal and other blood-purification tools, the device is integrated with RRT hemofiltration systems to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. The SCD selectively targets the most highly activated proinflammatory neutrophils and monocytes. These cells are then returned back into the body through the blood, and the body is signaled to lower its inflammatory environment and focus on repair. This unique immunomodulation approach may promote long-term organ recovery and eliminate the need for future RRT, including dialysis.
About SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, our ability to add additional direct end-user customers; the impact of our direct sales model on revenue; the ability of SCD to treat patients with AKI and other diseases; anticipated patient enrollment and the expansion of the clinical trial sites; anticipated patient populations and addressable markets for our products; the application of our technology beyond AKI; the anticipated Medicare and Medicaid reimbursement by CMS for patients enrolled in clinical trials; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to access funding under existing agreements; (vi) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Contact:
Alliance Advisors IR
Jody Cain
(310) 691-7100
Jcain@allianceadvisors.com
Financial Tables to Follow
SeaStar Medical Holding Corporation
Condensed Consolidated Balance Sheets
(in thousands, except for share and per-share amounts)
| As of September 30, 2024 | As of December 31, 2023 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 2,082 | $ | 176 | ||||
| Accounts receivable | 68 | $ | — | |||||
| Prepaid expenses | 1,466 | 2,132 | ||||||
| Total current assets | 3,616 | 2,308 | ||||||
| Other assets | 970 | 1,205 | ||||||
| Total assets | $ | 4,586 | $ | 3,513 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 3,687 | $ | 4,372 | ||||
| Accrued expenses | 2,291 | 1,523 | ||||||
| Contract liabilities | 550 | 100 | ||||||
| Notes payable, net of deferred financing costs | — | 565 | ||||||
| Convertible notes, current portion | — | 4,179 | ||||||
| Liability classified warrants | 110 | 2,307 | ||||||
| Total current liabilities | 6,638 | 13,046 | ||||||
| Notes payable, net of deferred financing costs | — | 4,143 | ||||||
| Convertible notes, net of current portion | — | 194 | ||||||
| Total liabilities | 6,638 | 17,383 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders' deficit | ||||||||
| Preferred stock - | — | — | ||||||
| Common stock - | 1 | 1 | ||||||
| Additional paid-in capital | 133,092 | 100,863 | ||||||
| Accumulated deficit | (135,145 | ) | (114,734 | ) | ||||
| Total stockholders' deficit | (2,052 | ) | (13,870 | ) | ||||
| Total liabilities and stockholders' deficit | $ | 4,586 | $ | 3,513 | ||||
SeaStar Medical Holding Corporation
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except for share and per-share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Net revenue | $ | 68 | $ | — | $ | 68 | $ | — | ||||||||
| Cost of goods sold | — | — | — | — | ||||||||||||
| Gross profit | 68 | — | 68 | — | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 2,336 | 1,087 | 6,367 | 4,798 | ||||||||||||
| General and administrative | 2,188 | 1,855 | 6,776 | 6,475 | ||||||||||||
| Total operating expenses | 4,524 | 2,942 | 13,143 | 11,273 | ||||||||||||
| Loss from operations | (4,456 | ) | (2,942 | ) | (13,075 | ) | (11,273 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 58 | — | 82 | — | ||||||||||||
| Interest expense | (272 | ) | (224 | ) | (497 | ) | (882 | ) | ||||||||
| Change in fair value of convertible notes | — | (291 | ) | (6,145 | ) | (291 | ) | |||||||||
| Change in fair value of warrants liability | 192 | 1,025 | (773 | ) | 1,784 | |||||||||||
| Change in fair value of forward option-prepaid forward contracts | — | (1,308 | ) | — | (1,308 | ) | ||||||||||
| Loss on extinguishment of convertible notes | — | (4,949 | ) | — | (4,949 | ) | ||||||||||
| Other income | — | 149 | — | 149 | ||||||||||||
| Change in the fair value of the forward purchase agreement derivative liability | — | 1,308 | — | — | ||||||||||||
| Total other income (expense), net | (22 | ) | (4,290 | ) | (7,333 | ) | (5,497 | ) | ||||||||
| Loss before provision for income taxes | (4,478 | ) | (7,232 | ) | (20,408 | ) | (16,770 | ) | ||||||||
| Provision for income taxes | — | — | 3 | 5 | ||||||||||||
| Net loss | $ | (4,478 | ) | $ | (7,232 | ) | $ | (20,411 | ) | $ | (16,775 | ) | ||||
| Net loss per share of common stock, basic and diluted | $ | (1.10 | ) | $ | (9.02 | ) | $ | (6.10 | ) | $ | (26.16 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 4,086,871 | 801,939 | 3,348,490 | 641,125 | ||||||||||||
SeaStar Medical Holding Corporation
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands, except for shares and per-share amounts)
| Nine Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (20,386 | ) | $ | (16,775 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities | ||||||||
| Amortization of deferred financing costs | 102 | 37 | ||||||
| Change in fair value of convertible notes (issued, converted and outstanding) | 6,145 | 291 | ||||||
| Change in fair value of forward purchase agreement derivative liability | — | 1,308 | ||||||
| Change in fair value of liability classified warrants (exercised and outstanding) | 773 | (1,784 | ) | |||||
| Stock-based compensation | 675 | 1,544 | ||||||
| Loss on extinguishment of convertible notes | — | 4,949 | ||||||
| Changes in operating assets and liabilities | ||||||||
| Accounts receivable | (68 | ) | — | |||||
| Other receivables | — | 12 | ||||||
| Prepaid expenses | 666 | 805 | ||||||
| Other assets | 235 | — | ||||||
| Accounts payable | (858 | ) | 3,115 | |||||
| Accrued expenses | 932 | 698 | ||||||
| Other liabilities | 495 | — | ||||||
| Net cash used in operating activities | (11,314 | ) | (5,800 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of convertible notes | 979 | 6,500 | ||||||
| Payment of convertible notes | (700 | ) | (282 | ) | ||||
| Proceeds from issuance of shares | 13,582 | 1,283 | ||||||
| Proceeds from exercise of convertible note warrants | 853 | — | ||||||
| Proceeds of pre-funded warrants | 3,766 | — | ||||||
| Payment of commitment fee - equity line of credit | — | (500 | ) | |||||
| Proceeds from sale of recycled shares | — | 1,870 | ||||||
| Proceeds from notes payable | — | 100 | ||||||
| Payment of notes payable | (5,260 | ) | (3,145 | ) | ||||
| Net cash provided by financing activities | 13,220 | 5,826 | ||||||
| Net increase in cash | 1,906 | 26 | ||||||
| Cash, beginning of period | 176 | 47 | ||||||
| Cash, end of period | $ | 2,082 | $ | 73 | ||||
| Supplemental disclosure of cash flow information | ||||||||
| Cash paid for interest | $ | 523 | $ | 707 | ||||
| Exercise of liability classified warrants | $ | 3,106 | $ | — | ||||
| Shares issued as payment of convertible notes | $ | 10,210 | $ | 4,348 | ||||
| Shares issued to settle forward option-prepaid forward contracts | $ | — | $ | 558 | ||||
| Board compensation settled in shares of common stock in-lieu-of-cash | $ | 210 | $ | — | ||||
| Issuance of convertible note warrants | $ | 586 | $ | 2,705 | ||||
# # #
FAQ
What was SeaStar Medical's (ICU) revenue in Q3 2024?
How many clinical sites are participating in SeaStar Medical's NEUTRALIZE-AKI trial?
What was SeaStar Medical's (ICU) cash position as of September 30, 2024?
When did SeaStar Medical (ICU) receive FDA clearance for QUELIMMUNE?
